Abstract: An insertion device for a cable in an existing pipe network includes a longitudinally stable flexible element that can be inserted into a pipe region of the pipe network, and on which a head part can be placed. The head part can be diverted to pass through regions of bends of the pipe. Placed on the flexible element is a coupling part to which coupling part the cable to be pulled can be coupled. The head part includes a base body having an elongated shape, which can be led from a stretched position into a bent position. The base body includes guide elements by which at least one pulling element is guided that is spaced apart from the bending axis of the base body. One end of the pulling element is held at one end region of the base body, whereas the other end is held at a drivable linear drive that is attached at the other end region of the base body. Disposed at the end region, remote from the flexible element, of the head part are a light source and a camera.

Abstract: The invention relates to the stem cells, embryonic stem cells in particular. It has been found that, when these stem cells are entrapped such that their proliferation is inhibited, they produce material which inhibits the proliferation of other, non-entrapped cells, including stem cells and neoplastic and/or hyperproliferative, but otherwise normal cells. It has also been found that entrapped cancer cells will produce material which inhibits the proliferation of stem cells. Further, it has been found that the entrapment of the stem cells inhibits their differentiation and thus the entrapment process can serve as a long-term storage device for maintaining the undifferentiated state of at least a portion of the entrapped cells.

Abstract: An insertion device for a cable in an existing pipe network includes a longitudinally stable flexible element that can be inserted into a pipe region of the pipe network, and on which a head part can be placed. The head part can be diverted to pass through regions of bends of the pipe. Placed on the flexible element is a coupling part to which coupling part the cable to be pulled can be coupled. The head part includes a base body having an elongated shape, which can be led from a stretched position into a bent position. The base body includes guide elements by which at least one pulling element is guided that is spaced apart from the bending axis of the base body. One end of the pulling element is held at one end region of the base body, whereas the other end is held at a drivable linear drive that is attached at the other end region of the base body. Disposed at the end region, remote from the flexible element, of the head part are a light source and a camera.

Abstract: An automated valuation system and method for: storing, in a database, a first feature element and an offered price for each of a plurality of specimens; generating, through the use of the first feature element and the offered price, a plurality of valuation coefficients, indicative of the actual value of each of the plurality of specimens; calculating, through the use of the plurality of valuation coefficients, the actual value of each of the plurality of specimens; and comparing, for each of the plurality of specimens, the actual value of the specimen to the offered price of the specimen to determine a cost indicator, wherein the cost indicator is indicative of the amount that the offered price of a specimen differs from the actual value of a specimen.

Abstract: The present invention relates to therapeutic combinations comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and BMS-200475 which have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.

Abstract: The present invention relates to therapeutic combinations comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and BMS-200475 which have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.